This section covers the ongoing investigations and findings of the ARID study.
The ARID Study Team are collaborating with colleagues at the University of Leeds and Randox. We are investigating potential biomarkers linked to the risk of AKI. This process involves testing samples using novel tests. The data is then analysed to establish whether the results are statistically significant.
The test methods being used are proven to give consistent results under development conditions. However they are not currently available for general use. The research will be used to identify biomarkers that may be suitable for use in future routine testing.
A lot of work has already taken place. First a representative sub-group had to be identified. The samples for this sub-group were then tested to establish whether the results are likely to be significant for the entire study population. This stage has been completed and is promising!
There are around 1,000 participants in the ARID Main Study, so the preparation of all the samples is a time-consuming task. When testing is complete the data will need to be carefully analysed before it will be possible to reach any conclusions. We anticipate that all the analysis steps will be finished in 2018.
So in 2019 watch this space.
All the participants currently active in both the ARID Pilot and ARID Main Studies we invited to attend presentations about the study progress and findings. In all over 1,100 letters were sent out. We were delighted with the response and quickly arranged for a second session.
The meetings were held at Riverside Court, Pride Park, Derby, in May and June 2017. There were three presentations about the study organisation; findings to date and pharmacy implications of AKI. The talks were followed by a Q&A session which continued as refreshments were provided.